Limits...
Neoadjuvant chemotherapy followed by D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis in gastric small cell carcinoma: A case report.

Xin K, Wei J, Wang H, Guan W, Liu B - Oncol Lett (2014)

Bottom Line: A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC).The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging.The patient experienced survival without progression in the 8-month follow-up.

View Article: PubMed Central - PubMed

Affiliation: The Comprehensive Cancer Center of Nanjing Drum-Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China.

ABSTRACT
A 60-year-old male was referred to Nanjing Drum-Tower Hospital (Nanjing, Jiangsu, China) due to the presence of gastric carcinoma. A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC). The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging. Following four cycles of neoadjuvant chemotherapy with irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days, 1, 21, 41 and 61) the patient underwent a D2 gastrectomy and an esophagojejunal Roux-en-Y anastomosis, followed by adjuvant chemotherapy. The patient experienced survival without progression in the 8-month follow-up. To the best of our knowledge, this is one of few cases of GSCC treated with the combination of neoadjuvant chemotherapy, surgery and adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus

(A and B) Post-surgical pathology of the mass revealing small-cell carcinoma of the stomach. (A) Magnification, ×100. (B) Magnification, ×200.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214484&req=5

f4-ol-08-06-2549: (A and B) Post-surgical pathology of the mass revealing small-cell carcinoma of the stomach. (A) Magnification, ×100. (B) Magnification, ×200.

Mentions: Following another multi-disciplinary discussion, the patient underwent a D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis. There was a 5×2×1-cm mass under the cardia of the stomach, in the lesser curvature. The serous membrane layer was complete and there were no metastatic nodules found in the liver, pancreas, spleen, kidneys, abdominal wall or pelvic cavity. The post-surgical pathology revealed that the tumor was 4×4×0.8 cm in size, invading the serosa, nerves and vessels of the stomach. The surgical margin was revealed to be tumor-free. Three metastasis-positive lymph nodes were found in 27 cleaned lymph nodes around the stomach. The pathological tumor-node-metastasis stage was stage IV (T4aN2M1; Fig. 4A and B). Following surgery, an enhanced CT scan was performed and the patient received four cycles of adjuvant chemotherapy combining irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days 1, 21, 41 and 61). The patient was followed up for ~8 months and is currently alive.


Neoadjuvant chemotherapy followed by D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis in gastric small cell carcinoma: A case report.

Xin K, Wei J, Wang H, Guan W, Liu B - Oncol Lett (2014)

(A and B) Post-surgical pathology of the mass revealing small-cell carcinoma of the stomach. (A) Magnification, ×100. (B) Magnification, ×200.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214484&req=5

f4-ol-08-06-2549: (A and B) Post-surgical pathology of the mass revealing small-cell carcinoma of the stomach. (A) Magnification, ×100. (B) Magnification, ×200.
Mentions: Following another multi-disciplinary discussion, the patient underwent a D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis. There was a 5×2×1-cm mass under the cardia of the stomach, in the lesser curvature. The serous membrane layer was complete and there were no metastatic nodules found in the liver, pancreas, spleen, kidneys, abdominal wall or pelvic cavity. The post-surgical pathology revealed that the tumor was 4×4×0.8 cm in size, invading the serosa, nerves and vessels of the stomach. The surgical margin was revealed to be tumor-free. Three metastasis-positive lymph nodes were found in 27 cleaned lymph nodes around the stomach. The pathological tumor-node-metastasis stage was stage IV (T4aN2M1; Fig. 4A and B). Following surgery, an enhanced CT scan was performed and the patient received four cycles of adjuvant chemotherapy combining irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days 1, 21, 41 and 61). The patient was followed up for ~8 months and is currently alive.

Bottom Line: A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC).The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging.The patient experienced survival without progression in the 8-month follow-up.

View Article: PubMed Central - PubMed

Affiliation: The Comprehensive Cancer Center of Nanjing Drum-Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China.

ABSTRACT
A 60-year-old male was referred to Nanjing Drum-Tower Hospital (Nanjing, Jiangsu, China) due to the presence of gastric carcinoma. A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC). The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging. Following four cycles of neoadjuvant chemotherapy with irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days, 1, 21, 41 and 61) the patient underwent a D2 gastrectomy and an esophagojejunal Roux-en-Y anastomosis, followed by adjuvant chemotherapy. The patient experienced survival without progression in the 8-month follow-up. To the best of our knowledge, this is one of few cases of GSCC treated with the combination of neoadjuvant chemotherapy, surgery and adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus